Superworth

Unicycive Therapeutics price to book ratio UNCY

Market value divided by the book value of the company's net assets, since 2021.

Today, Nov 2, 2026
1.8×
5-year median
2.8×
Against its 5-year history
31st
percentile: 0 is its lowest day, 100 its highest
5-year range
0.8× to 18.4×
Peer median
1.5×

Unicycive Therapeutics' price to book ratio is 1.8× as of Nov 2, 2026.

That is below its 5-year median of 2.8×, lower than on 69% of days in the last 5 years.

Over that time it ranged from 0.8× in May 2022 to 18.4× in Feb 2024.

The median for 10 large drugmakers of a similar size is 1.5×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far1.8×1.8×6.6×
20253.5×2.0×10.5×
20243.0×1.7×18.4×
20238.9×1.5×8.9×
20221.8×0.8×2.4×
20211.6×1.4×2.3×

Against its peers

Companies in Drug Manufacturers - General nearest Unicycive Therapeutics' size, closest first, today.

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Unicycive Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.